Elizabeth Buck, Ph.D. - Black Diamond Therapeutics
WEBElizabeth Buck, Ph.D., serves as the Chief Scientific Officer of Black Diamond Therapeutics. Liz was instrumental in developing Black Diamond’s MAP platform through which she made critical discoveries leading to the understanding of the properties of allosteric mutations in oncogene activation.
Executive Team - Black Diamond Therapeutics
WEBBlack Diamond’s team is comprised of driven and dedicated experts. Skip Navigation ... Elizabeth Buck, Ph.D. Co-Founder, Chief Scientific Officer. Brent Hatzis-Schoch. Chief Operating Officer, General Counsel. Erika Jones, CPA. Senior Vice President of Finance. Elizabeth L. Montgomery.
Elizabeth Buck - Black Diamond Therapeutics | LinkedIn
WEBView Elizabeth Buck’s profile on LinkedIn, a professional community of 1 billion members. Experience: Black Diamond Therapeutics · Location: United States · 307 connections on LinkedIn.
- Connections: 307
- Location: Black Diamond Therapeutics
WEBBlack Diamond Therapeutics is Developing BDTX-1535 as a Brain Penetrant, Potent Inhibitor of Oncogenic EGFR Mutations Potential to treat patients with NSCLC harboring osimertinib-resistant C797S mutation with or without brain metastases
Elizabeth Buck - Founder, Executive Vice President @ Black Diamond ...
WEBElizabeth Buck is the Founder, Executive Vice President of Black Diamond Therapeutics. Dr. Buck received her undergraduate degree in physics...
Black Diamond's EFGR-targeted glioblastoma drug candidate slows …
WEBNov 23, 2020 · About half of glioblastoma tumors have EGFR variants, explained Elizabeth Buck, Ph.D., executive vice president of discovery and translational sciences, during the presentation (PDF). BDTX-1535...
Elizabeth Buck - Co-Founder & Chief Scientific Officer at Black Diamond ...
WEBElizabeth Buck, Ph.D., serves as the Chief Scientific Officer of Black Diamond Therapeutics. Liz was instrumental in developing Black Diamond’s MAP platform through which she made critical discoveries leading to the understanding of the properties of allosteric mutations in oncogene activation.
Elizabeth Buck (0000-0002-6022-1871) - ORCID
WEBElizabeth Buck, Ph.D., serves as the Chief Scientific Officer of Black Diamond Therapeutics. Liz was instrumental in developing Black Diamond’s MAP platform through which she made critical discoveries leading to the understanding of the properties of allosteric mutations in oncogene activation.
Black Diamond Therapeutics to Present Pre-Clinical Data on Lead …
WEBOct 12, 2020 · Title: BDTX-189, a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. Presenter: Elizabeth Buck, Ph.D., Co-Founder and Executive Vice President, Discovery and Translational Sciences, Black Diamond Therapeutics. Session: Closing Session: New Drugs on the Horizon.
Black Diamond Therapeutics Presents Data From its Program …
WEBMar 29, 2019 · Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant’s Ridgeline Discovery Engine in Basel, Switzerland.
- Some results have been removed
Skip to content